Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXTRIPHYLLINE vs AEROLATE III
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
Treatment of bronchial asthma,Chronic bronchitis,Pulmonary emphysema,Apnea of prematurity (off-label)
Treatment and prophylaxis of bronchospasm associated with asthma, chronic bronchitis, and emphysema,Off-label: Apnea of prematurity (oral/IV theophylline)
200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
Adults: 3-5 hours (non-smokers); smokers: 4-6 hours; children: 1-4 hours; neonates: 20-30 hours; congestive heart failure or hepatic cirrhosis: prolonged up to 10-20 hours. Note: Oxtriphylline is a choline salt of theophylline, and its half-life reflects theophylline kinetics.
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Hepatic via CYP1A2 and CYP2E1; exhibits nonlinear pharmacokinetics at high doses.
Primarily hepatic via cytochrome P450 1A2 (CYP1A2); also CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics.
Renal: ~70-80% as unchanged drug and metabolites (including theophylline); biliary/fecal: minimal (<10%)
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Approximately 40-60% bound to plasma albumin; decreases in neonates and patients with hepatic disease
92-96%, primarily to albumin and alpha-1-acid glycoprotein
0.45-0.7 L/kg; approximates total body water; increased in premature infants (0.8-1.0 L/kg) and in cirrhosis
Vd 1.5-2.0 L/kg, indicating extensive tissue distribution
Oral: 100%; rectal: >90%
Oral: 40-50%; Inhalation: 20-30%
For GFR 30-50 m L/min: reduce dose by 50% and extend interval to every 8-12 hours. For GFR <30 m L/min: avoid use or reduce to 200 mg every 12 hours with close monitoring.
No adjustment needed for GFR >30 m L/min. For GFR 10-30 m L/min: use 50% of usual dose. For GFR <10 m L/min: avoid use.
Child-Pugh A: no adjustment needed. Child-Pugh B: reduce dose by 50% and monitor levels. Child-Pugh C: contraindicated or use with extreme caution, maximum 200 mg every 12 hours.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
For children >1 year: 5 mg/kg orally every 6 hours; maximum 200 mg per dose. For infants 6-12 months: 4 mg/kg every 8 hours. Not recommended for neonates.
Children 2-11 years: 1 inhalation (100 mcg) twice daily via metered-dose inhaler. Children 12 years and older: same as adult.
Initiate at 200 mg orally every 8-12 hours; titrate slowly, monitor for CNS excitation and arrhythmias. Use lower end of dosing range due to reduced clearance.
No specific dose adjustment but monitor for increased systemic effects; start at lowest effective dose.
None.
No FDA black box warning.
Seizures: Risk increases with high serum levels (particularly >20 mcg/m L) and in patients with preexisting seizure disorders.,Cardiotoxicity: Includes ventricular arrhythmias and atrial fibrillation; risk increased with underlying cardiac disease or hypoxemia.,Gastrointestinal effects: Nausea, vomiting, and diarrhea are common; may indicate toxicity.
Monitor serum theophylline concentrations due to narrow therapeutic index; risk of toxicity at levels >20 mcg/m L; use caution in patients with cardiac disease, hepatic impairment, or seizures; may exacerbate arrhythmias; drug interactions with cimetidine, fluoroquinolones, macrolides, allopurinol, oral contraceptives, smoking, and others.
Hypersensitivity to oxitriphylline or any xanthine derivative,Acute myocardial infarction,Uncontrolled arrhythmias,Preexisting seizure disorder (relative)
Hypersensitivity to theophylline or any component; pre-existing cardiac arrhythmias (e.g., ventricular tachycardia); recent myocardial infarction; uncontrolled seizure disorders.
Avoid or limit high-caffeine foods and beverages (coffee, tea, chocolate, cola) as they may potentiate side effects. Also avoid chargrilled meats and cruciferous vegetables (e.g., broccoli, cabbage) as they may alter theophylline metabolism.
Avoid significant intake of caffeine-containing foods/beverages (coffee, tea, cola, chocolate) as they may increase CNS stimulation and risk of toxicity. Charcoal-broiled foods and a high-protein diet may increase clearance. Maintain consistent dietary patterns; avoid extremes of protein/carbohydrate intake.
Pregnancy Category C. No well-controlled studies in humans. Animal studies have shown adverse effects (fetal resorption, skeletal anomalies) at high doses. Risk cannot be ruled out; use only if clearly needed. First trimester: potential for teratogenicity based on animal data. Second/third trimesters: potential for respiratory alkalosis and electrolyte disturbances in fetus due to maternal alkalosis; avoid near term as may cause fetal tachycardia.
AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal heart rate, jitteriness, and risk of neonatal apnea with high maternal serum concentrations (>15 mcg/m L). Avoid near term due to prolonged neonatal half-life.
Excreted into breast milk in small amounts. M/P ratio not determined. Use with caution; monitor infant for irritability, insomnia, and jitteriness. American Academy of Pediatrics considers compatible with breastfeeding, but preferable to use lowest effective dose.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach 50% of maternal levels; risk of irritability and sleep disturbances in nursing infants. Use with caution and monitor infant for signs of toxicity.
Pregnancy decreases theophylline clearance by approximately 20-30% due to reduced hepatic metabolism and increased volume of distribution. Dose reduction may be required to achieve therapeutic levels; monitor serum levels frequently. Avoid loading doses in early labor due to prolonged half-life.
Pregnancy may increase theophylline clearance due to enhanced hepatic metabolism and increased renal blood flow. Dose adjustments are often required: monitor serum levels regularly and adjust dose to maintain therapeutic levels. Typically, dose may need to be increased by 20-50% in second and third trimesters.
Oxtriphylline is a bronchodilator (xanthine derivative) with similar efficacy to theophylline. Monitor serum theophylline levels (target 5-15 mcg/m L) due to narrow therapeutic index. Caution in hepatic impairment, heart failure, and elderly. Drug interactions include CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) and inducers (e.g., carbamazepine, rifampin). Avoid rapid IV administration to prevent hypotension and arrhythmias.
AEROLATE III (theophylline) is a bronchodilator with a narrow therapeutic index; monitor serum levels (target 10-20 mcg/m L). Caffeine and smoking increase clearance; hepatic impairment, heart failure, and certain drugs (e.g., cimetidine, fluoroquinolones) decrease clearance. Avoid use in patients with active peptic ulcer or seizure disorders. Titrate dose slowly to minimize nausea, vomiting, and arrhythmias.
Take exactly as prescribed; do not crush or chew enteric-coated tablets.,Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, or seizures.,Do not stop abruptly; taper under medical supervision.,Keep a diary of peak flow readings if used for asthma.
Take this medication exactly as prescribed; do not crush or chew extended-release tablets.,Avoid consuming large amounts of caffeine (coffee, tea, chocolate) as it may increase side effects like jitteriness and insomnia.,Inform your doctor if you experience nausea, vomiting, rapid heartbeat, or seizures.,Do not stop taking this medication abruptly; taper under medical supervision.,Keep all appointments for blood tests to monitor theophylline levels.,Avoid smoking or using nicotine products, as they affect how the medication works.,Carry a list of all medications you take, as many can interact with theophylline.
"Oxtriphylline, a xanthine derivative, is a prodrug of theophylline and is primarily metabolized by hepatic cytochrome P450 enzymes, notably CYP1A2 and CYP3A4. Nevirapine, a non-nucleoside reverse transcriptase inhibitor, induces CYP3A4 and other metabolic enzymes, potentially increasing the clearance of oxtriphylline's active metabolite theophylline. This reduction in theophylline exposure may decrease its bronchodilator efficacy, leading to worsening of respiratory symptoms in patients with asthma or COPD."
"Oxtriphylline, a xanthine bronchodilator, is metabolized primarily by CYP1A2 and CYP3A4. Azithromycin, a macrolide antibiotic, can inhibit CYP3A4, leading to decreased clearance of oxtriphylline and increased plasma concentrations. This may result in dose-related toxicity, including nausea, vomiting, tachycardia, and seizures."
"Oxtriphylline, a xanthine derivative used as a bronchodilator, may inhibit the metabolism of abiraterone, a CYP3A4 substrate, leading to increased serum concentrations of abiraterone. This elevation can potentiate the risk of abiraterone-related adverse effects such as hepatotoxicity, hypertension, hypokalemia, and fluid retention. Additionally, Oxtriphylline's own clearance may be affected, increasing the likelihood of xanthine toxicity manifesting as nausea, vomiting, or cardiac arrhythmias."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OXTRIPHYLLINE vs AEROLATE III, answered by our medical review team.
OXTRIPHYLLINE is a Bronchodilator that works by Xanthine derivative that inhibits phosphodiesterase, increasing intracellular cyclic AMP; also antagonizes adenosine receptors, leading to bronchodilation and stimulation of respiratory drive.. AEROLATE III is a Bronchodilator that works by AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular c AMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OXTRIPHYLLINE and AEROLATE III depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OXTRIPHYLLINE is: 200 mg orally every 6 hours, or 400 mg orally every 8-12 hours; maximum 600 mg per dose.. The standard adult dose of AEROLATE III is: Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OXTRIPHYLLINE and AEROLATE III in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OXTRIPHYLLINE is classified as Category C. Pregnancy Category C. No well-controlled studies in humans. Animal studies have shown adverse effects (fetal resorption, skeletal anomalies) at high doses. Risk cannot be ruled out. AEROLATE III is classified as Category C. AEROLATE III (theophylline) is FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be ruled out. Second/third trimesters: Increased fetal h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.